Independent
Tenure on this board
5.5 yrs
3 nominees · 2 ballot items.
Elect three Class III directors (Gregory R. Reyes, M.D., Ph.D.; Tamara A. Favorito; and Gregory D. Gorgas) and approve an amendment to the Articles of Incorporation to increase authorized common stock from 166,666,667 to 500,000,000.
To elect three Class III director nominees—Gregory R. Reyes, M.D., Ph.D.; Tamara A. Favorito; and Gregory D. Gorgas—to serve three-year terms as Class III directors until the Company’s 2029 Annual Meeting of Stockholders (or until their successors are duly elected and qualified) and until their earlier resignation or removal.
Approve an amendment to the Articles to increase the number of authorized shares of Common Stock from 166,666,667 to 500,000,000.
This management proposal asks stockholders to approve an amendment to the company’s Articles of Incorporation increasing authorized common shares from 166,666,667 to 500,000,000. Management and the Board argue the increase will provide near‑term and long‑term flexibility to raise capital through public or private financings, to issue equity in connection with collaborations or strategic transactions, and to grant equity incentives for employee recruitment and retention; they note no definitive plans currently exist other than an equity line previously disclosed. The proposal would, if approved, allow the Board to issue additional shares without further shareholder approval (subject to law and Nasdaq rules), which the Board frames as operational flexibility but which could also be used opportunistically and could have anti‑takeover effects by diluting a hostile bidder. The company discloses the potential dilutive effects on earnings per share, book value and voting power if additional shares are issued. The Board represents the proposal was not prompted by any specific hostile takeover attempt and recommends approval, while cautioning that issuance of additional shares could also limit opportunities for shareholders to receive takeover premiums. The filing explains voting mechanics and that the amendment will be effective upon filing with the Nevada Secretary of State, and that approval requires a majority of votes cast. From a governance perspective, the board’s unfettered ability to issue newly authorized shares without further shareholder approval raises shareholder rights and anti‑dilution concerns; however, for a small, capital‑constrained biotech, the increased authorization can be a practical tool to execute financings and strategic transactions quickly. Investors evaluating the proposal should weigh the company’s financing needs and limited existing authorized-share runway against the governance risk that a large pool of unissued shares could be used in ways adverse to existing holders.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Kathmere Capital Management, LLC | 0.6% | 13,250 | $100K |
| 2 | JANE STREET GROUP, LLC | 0.6% | 13,078 | $99K |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 0.4% | 10,129 | $77K |
| 4 | VANGUARD FIDUCIARY TRUST CO | 0.1% | 3,139 | $24K |
| 5 | CITIGROUP INC | 0.1% | 3,076 | $23K |
| 6 | Tower Research Capital LLC (TRC | 0.1% | 1,424 | $11K |
| 7 | Tower Research Capital LLC (TRC | 0.1% | 1,402 | $11K |
| 8 | Altshuler Shaham Ltd | 0.0% | 889 | $484K |
| 9 | Clear Street Group Inc. | 0.0% | 100 | $758 |
| 10 | ROTHSCHILD INVESTMENT LLC | 0.0% | 2 | $15 |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.